雷贝拉唑联合莫沙比利治疗青年慢性胃炎的临床效果及安全性研究  

Clinical Effect and Safety of Rabeprazole Combined with Mosapride in theTreatment of Young Patients with Chronic Gastritis

作　　者：李红梅[1] LI Hong-mei(School Hospital,Zaozhuang University,Zaozhuang 277160,China)

机构地区：[1]枣庄学院校医院,山东枣庄277160

出　　处：《枣庄学院学报》2021年第2期56-59,共4页Journal of Zaozhuang University

摘　　要：目的探讨雷贝拉唑联合莫沙比利对青年慢性胃炎的治疗效果及临床安全性.方法择取青年患者124例,均确诊为慢性胃炎,随机分两组.对照组予以雷贝拉唑干预,观察组在对照组基础上加用莫沙必利干预.对比两组患者症状缓解用时、治疗效果及副反应发生率.结果观察组的饱胀、腹痛、烧心、嗳气、食欲不振等临床症状缓解时长显著短于对照组,治疗效果及Hp根除率较对照组高,副反应发生率低于对照组(P<0.05).结论对青年慢性胃炎者采用雷贝拉唑与莫沙比利联合干预能够有效缩短症状恢复时长,且不良反应较低,效果满意,值得临床应用.Objective To explore the therapeutic effect and clinical safety of rabeprazole combined with mosapride on chronic gastritis in young people.Method Selected 124 young patients with chronic gastritis in our hospital.The control group was treated with rabeprazole,The observation group was treated with rabeprazole and mosapride in combination.Compare the symptom relief time of the two groups of patients,treatment effect and incidence of adverse reactions.Result The clinical symptom relief time of the observation group was significantly shorter than that of the control group,the treatment efficiency is higher than the control group,the incidence of adverse reactions is lower than the control group(P<0.05).Conclusion The combination of rabeprazole and mosapride in the treatment of chronic gastritis is effective and has fewer adverse reactions.

关 键 词：慢性胃炎 雷贝拉唑 莫沙比利 

分 类 号：K58[历史地理—历史学]